Topic report
GLP-1 supply chain
Who makes, fills, equips and follows the two franchises that reshaped the category.
Brief:
Beyond the two originators, the GLP-1 cycle pulls on manufacturing capacity, fill-finish, devices and the tools suppliers. The theme maps that chain and asks which links are already reflected in prices.
Not to be missed:
nothing specified
Head to head
The names with real exposure, most likely to succeed first. Everything
else the report found is in the full table below.
| Company | Odds | Why | What sets it apart | If it works | If it doesn’t |
|---|---|---|---|---|---|
|
Eli Lilly and Company
Core
|
already earning | Franchise revenue and the manufacturing capital programme are disclosed every quarter. | The broadest pipeline behind the franchise of any name on the list, including the oral programme. | Capacity comes online on schedule and the oral candidate reaches the market. | Supply stays constrained longer than planned while a competitor's oral product lands first. |
|
Novo Nordisk A/S
Core
|
already earning | Franchise volumes and the fill-finish capacity additions are reported. | The most concentrated expression of the theme on the list, which cuts both ways. | Pricing holds while volume growth continues into new markets. | Price competition arrives before the next generation of products does. |
|
Thermo Fisher Scientific Inc
Satellite
|
strong | The bioprocess segment is reported separately and its growth is visible. | Sells to every manufacturer in the chain rather than to one franchise. | Capacity build across the chain keeps the consumables run-rate growing. | The capacity build pauses and the consumables run-rate flattens with it. |
v1 ·
generated 2026-10-04 14:53 by Toviya ·
8 verified names
Scope
In scope: the listed companies that own the approved franchises, that supply the tools and consumables to make and fill them, and that run follow-on programmes in the same category. Out of scope: the payers and the retail pharmacies, which are a different theme.
The space
Two approved franchises grew faster than the capacity to make them, and the constraint moved from demand to manufacturing. The originators report the franchise numbers and the capital programmes every quarter; the tools companies report the bioprocess segment that supplies them; the follow-on programmes at other pharma companies are the speculative end of the same chain.
Why now
Capacity additions and launch cadence make the theme measurable now: the originators disclose volumes and the manufacturing capital, and the oral programmes have dated readouts, so the thesis can be checked against reported numbers rather than forecasts.
Timeline
The originators' franchises reached scale first; the manufacturing build followed a year behind, and the oral and combination programmes at other companies are the latest and least certain part of the chain.
How it works
A peptide is made, filled into a device under sterile conditions and distributed through specialty channels. Each step has its own supplier set and its own lead time; fill-finish capacity has been the binding constraint.
How we got here
Demand outran the launch plans, supply was rationed and the originators committed multi-year manufacturing capital. The tools suppliers saw the orders a year before the capacity came online.
Where it stands today
Capacity is still being added; the first oral candidates have dated readouts; pricing is under discussion with payers in the largest market.
The open arguments
- Whether pricing holds as competition and oral formulations arrive.
- How much of the manufacturing build is captured by listed tools companies rather than private contractors.
- Whether the follow-on programmes at other pharma companies are differentiated or late.
Value chain
Each link was searched separately for public companies — which is what
surfaces the suppliers a single query omits.
Originators & franchise owners
The two companies that own the approved molecules and the franchise economics.
Pricing and volume are the whole story; manufacturing capacity is the constraint.
Contract manufacturing & fill-finish
Sterile fill-finish and device assembly capacity for injectable peptides, mostly private or inside larger groups.
Multi-year take-or-pay contracts; the capacity is being built now.
Tools, consumables & bioprocess
The equipment and consumables that scale peptide and device production.
Diluted inside large tools companies; the segment growth is the tell.
Follow-on and combination programmes
Oral and next-generation candidates at other pharma companies.
Pre-revenue for this theme; the read rests on trial milestones.
The names
Tier and role rank each name within this theme — they are not
buy/sell/hold calls.
Core — the way to own this theme
(2)
| Ticker | Company | Segment | Role | Odds | Mkt cap | Listing | Ours | The read |
|---|---|---|---|---|---|---|---|---|
| Eli Lilly and Company | Originators & franchise owners | pure play | already earning | $1.0T | US listed | HELD |
Owner of one of the two approved franchises; the quarter's growth and the capacity build are both in the reported numbers.
DifferentThe broadest pipeline behind the franchise of any name on the list, including the oral programme.
BasisFranchise revenue and the manufacturing capital programme are disclosed every quarter.
Works ifCapacity comes online on schedule and the oral candidate reaches the market.
Fails ifSupply stays constrained longer than planned while a competitor's oral product lands first.
|
|
| Novo Nordisk A/S | Originators & franchise owners | pure play | already earning | $165.7B | US listed | HELD |
The other originator; the franchise is the company, so the exposure is as direct as it gets.
DifferentThe most concentrated expression of the theme on the list, which cuts both ways.
BasisFranchise volumes and the fill-finish capacity additions are reported.
Works ifPricing holds while volume growth continues into new markets.
Fails ifPrice competition arrives before the next generation of products does.
|
Satellite — real exposure, with a qualifier
(1)
| Ticker | Company | Segment | Role | Odds | Mkt cap | Listing | Ours | The read |
|---|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc | Tools, consumables & bioprocess | diversified | strong | $237.0B | US listed | HELD |
Bioprocess tools and consumables for peptide and device manufacturing sit inside a large tools company.
DifferentSells to every manufacturer in the chain rather than to one franchise.
BasisThe bioprocess segment is reported separately and its growth is visible.
Works ifCapacity build across the chain keeps the consumables run-rate growing.
Fails ifThe capacity build pauses and the consumables run-rate flattens with it.
|
Watch — something has to happen first
(3)
| Ticker | Company | Segment | Role | Odds | Mkt cap | Listing | Ours | The read |
|---|---|---|---|---|---|---|---|---|
| AbbVie Inc. | Follow-on and combination programmes | diversified | even | $471.0B | US listed | HELD |
A large pharma with adjacent metabolic and immunology franchises; the theme is a small part of a wide portfolio.
DifferentThe exposure is indirect; the read is about how the consumer and payer shift reaches other categories.
BasisThe relevant programmes are early and the segment is small inside the group's numbers.
Works ifAn in-house programme reaches a late-stage readout.
Fails ifThe programme stays early and the theme never reaches the group's revenue line.
|
|
| Pfizer, Inc. | Follow-on and combination programmes | diversified | even | $157.3B | US listed | HELD |
An oral candidate programme inside a diversified pharma; the theme is one option among many.
DifferentA different route to the same market, through an oral formulation rather than an injectable.
BasisTrial milestones are public; the commercial case rests on readouts still ahead.
Works ifThe oral candidate reads out well and reaches a filing.
Fails ifThe candidate is discontinued or arrives behind the originators' own oral products.
|
|
| Regeneron Pharmaceuticals, Inc. | Follow-on and combination programmes | diversified | long shot | $74.8B | US listed | — |
Combination and muscle-preserving programmes that sit beside the originators' products.
DifferentA complement to the franchise rather than a competitor to it.
BasisThe programmes are early-stage; the odds rest on readouts, not revenue.
Works ifA combination programme shows a differentiated profile in a mid-stage trial.
Fails ifThe programmes stay early and the theme is expressed through other names.
|
Avoid — the exposure is not what it looks like
(2)
| Ticker | Company | Segment | Role | Odds | Mkt cap | Listing | Ours | The read |
|---|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorpor | Follow-on and combination programmes | diversified | long shot | $127.1B | US listed | pipeline |
On the list because of the category; the company's own franchise is elsewhere.
DifferentThe least direct exposure on the list.
BasisThe metabolic programme is small relative to the company's core franchise.
Works ifA late-arriving programme reaches the market in a niche the originators left open.
Fails ifThe programme stays a footnote to the core franchise.
|
|
| Moderna, Inc. | Follow-on and combination programmes | speculative | long shot | $78.4B | US listed | pipeline |
A platform company with early metabolic work; the theme is not the business.
DifferentThe read is about the platform, not about this theme.
BasisPre-revenue for this theme; the programmes are early.
Works ifA platform programme reaches a differentiated readout.
Fails ifThe programmes stay early while the platform's own economics decide the shares.
|
How we would play it
The desk's read is that the originators are the direct expression and carry the clearest reported numbers; the tools link gives exposure across every manufacturer with dilution inside a wider business; the follow-on names are watch items at most until a readout lands. This is a description of where the exposure sits, not a sizing instruction.
What must be true
- Demand keeps growing into new markets as capacity is added.
- Pricing holds through the arrival of oral formulations.
- The manufacturing build is captured by suppliers the desk can own.
What would kill it
- A pricing reset in the largest market that compresses the franchise economics.
- A safety signal that changes the label for the category.
- An oral competitor that lands ahead of the originators' own.
What to watch
- Franchise volumes and the manufacturing capital programme each quarter.
- Bioprocess segment growth at the tools suppliers.
- Dated readouts on the oral and combination programmes.
- Payer negotiations in the largest market.